Could a common bone drug help rare anemia patients?
NCT ID NCT07471516
First seen Mar 15, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This early study tests whether zoledronic acid, a drug usually used for bone health, can improve anemia in adults with congenital dyserythropoietic anemia (CDA), a rare inherited blood disorder. Only 2 participants will receive the drug intravenously every 4 weeks for 4 doses. The goal is to see if it raises hemoglobin levels and reduces the need for blood transfusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL DYSERYTHROPOIETIC ANEMIA (CDA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.